Is Infinium Pharma overvalued or undervalued?

As of 15 September 2025, Infinium Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, especially when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE ratio of 45.26, an EV to EBITDA of 25.27, and a ROCE of 21.16%, which suggest strong operational efficiency despite a high valuation relative to earnings.
In terms of peer comparison, Infinium Pharma's PE ratio significantly exceeds that of Sun Pharma, which stands at 33.52, and is also higher than Cipla's attractive PE of 23.18. This positioning, alongside a PEG ratio of 0.00, indicates that the market may be underestimating Infinium's growth potential. Despite recent stock performance trailing the Sensex over the year, with a return of 26.54% compared to the Sensex's -1.13%, the overall valuation metrics suggest that Infinium Pharma presents a compelling investment opportunity.